2-(Azetidin-1-yl)-5-bromopyrimidine → HCID 70652104, 화합물
반응식
[OH:1][C:2]([CH3:35])([CH3:34])[CH2:3][C@@:4]1([C:28]2[CH:33]=[CH:32][CH:31]=[CH:30][CH:29]=2)[O:9][C:8](=[O:10])[N:7]([C@H:11]([C:13]2[CH:18]=[CH:17][C:16](B3OC(C)(C)C(C)(C)O3)=[CH:15][CH:14]=2)[CH3:12])[CH2:6][CH2:5]1.[N:36]1([C:40]2[N:45]=[CH:44][C:43](Br)=[CH:42][N:41]=2)[CH2:39][CH2:38][CH2:37]1>>[N:36]1([C:40]2[N:45]=[CH:44][C:43]([C:16]3[CH:15]=[CH:14][C:13]([C@@H:11]([N:7]4[CH2:6][CH2:5][C@:4]([CH2:3][C:2]([OH:1])([CH3:34])[CH3:35])([C:28]5[CH:33]=[CH:32][CH:31]=[CH:30][CH:29]=5)[O:9][C:8]4=[O:10])[CH3:12])=[CH:18][CH:17]=3)=[CH:42][N:41]=2)[CH2:39][CH2:38][CH2:37]1참가 물질
3
실험 절차
The title compound was prepared following a procedure analogous to Example 31 using (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-{(S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl}-1,3-oxazinan-2-one and 2-(azetidin-1-yl)-5-bromopyrimidine. LC (method 5): tR=1.48 min; Mass spectrum (ESI+): m/z=487 [M+H]+; 1H NMR (CD3OD) δ 0.95 (s, 3H), 1.23 (s, 3H), 1.55 (d, 3H), 2.14 (s, 2H), 2.20 (m, 1H), 2.40-2.60 (m, 4H), 3.04 (m, 1H), 4.33 (m, 4H), 5.57 (q, 1H), 7.08 (d, 2H), 7.25-7.40 (m, 7H), 8.62 (s, 2H).